A new version of ReproZip has been released, adding some bugfixes and new commands related to distributed or server experiments.
When reporting research findings, scientists document the steps they followed so that others can verify and build upon the research. When those steps have been described in sufficient detail that others can retrace the steps and obtain similar results, the research is said to be reproducible. Computers play a vital role in many research disciplines and present both opportunities and challenges for reproducibility. With a broad scientific audience in mind, we describe strengths and limitations of each approach, as well as circumstances under which each might be applied. No single strategy is sufficient for every scenario; thus we emphasize that it is often useful to combine approaches.
PDBF documents are a hybrid format. They are a valid PDF and a valid HTML page at the same time. You can now optionally add an VirtualBox OVA file with a complete operating system to the PDBF document. Yes, this means that the resulting file is a valid PDF, HTML, and OVA file at the same time. If you change the file extension to PDF and open it with an PDF viewer, you can see the static part of the document.
A ReproZip demo has been accepted at SIGMOD 2016: "ReproZip: Computational Reproducibility With Ease." F. Chirigati, R. Rampin, D. Shasha, and J. Freire.
For the past decade, scientists have been worried about the so-called replication crisis. Enter the Preclinical Reproducibility and Robustness channel. The website launched the first week in February with the goal of publishing the results of replication studies. The journal wants to keep scientists accountable for their work.
Elemental Machines, which develops smart laboratory technology, launched a new suite of tools that that measure environmental variables such as temperature and humidity—both of which are not traditionally accounted for in scientific experiments. By “debugging” the lab environment, the company believes it can improve experimental reproducibility, therefore reducing the time and cost of marketing new drugs and therapies. Elemental Machines recently raised $2.5 million in seed capital to support the development of the new suite of tools, which is called the EM Suite.